learn more at prudential.com >>> roundup and monsanto maker bayer under scrutiny the ceo highlighting quote broken area, high debt load and ongoing litigation following the 2018 acquisition of monsanto saying these are greatly limiting the company's growth prospects moving forward. talk about it with bill anderson, chairman and ceo of bayer. bill, great to have you. you've been in the job since i believe june of last year. this capital markets day was a big day for you. let's start off with what may have surprised some, the decision in no way to pursue a breakup of the company. why the choice to keep it all together, whether it's consumer health, farm or crop sciences? >> yeah. thanks, david, for having me on the show today. as you said, an important question for sure. maybe to remind folks bayer is a company playing an important role in medicine, in agriculture, in providing consumer with self-care options, and the idea of a breakup has that appeal of, you know, creating pure play companies, which makes a lot of sense, but it's also important to start with where we are. where we are